Evaluation of a Clinical Outcome of resistant gastroesophageal reflux disease after treatment with full thickness endoscopic device

Abstract

Gastroesophageal reflux disease (GERD) is the most common esophageal disorder, affecting more than 20% of the population worldwide. GERD symptoms vary from simple heartburn and epigastric pain to more complex clinical situations, with a combination of other various extra-esophageal symptoms that include hoarseness, chronic cough, pharyngitis and laryngitis, and asthma. In addition to its impact on quality of life, chronic GERD is a risk factor for numerous adverse events, such as esophageal stricture formation, Barrett's metaplasia and esophageal adenocarcinoma, thus necessitating adequate diagnosis and treatment of this common entity. The goals of clinical management of gastroesophageal disease (GERD) are prompt symptom relief, long-term symptom control, and maintenance of esophageal healing. The standard treatments for gastroesophageal reflux disease (GERD) consist of the prescription of H2-receptor antagonists or proton-pump inhibitors (PPI). Daily use of proton pump inhibitors (PPI) is generally effective in the treatment of the majority of patients with gastroesophageal reflux disease (GERD); however, up to 40% have persisting symptoms.